Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 77,000 shares, a growth of 40.8% from the October 31st total of 54,700 shares. Based on an average trading volume of 337,300 shares, the short-interest ratio is currently 0.2 days. Currently, 5.8% of the shares of the company are sold short.

Sonoma Pharmaceuticals Price Performance

NASDAQ:SNOA remained flat at $2.79 during mid-day trading on Friday. 36,732 shares of the company traded hands, compared to its average volume of 201,845. The stock’s 50 day moving average is $2.90 and its 200 day moving average is $1.54. The stock has a market capitalization of $3.74 million, a PE ratio of -0.56 and a beta of 1.38. Sonoma Pharmaceuticals has a 12-month low of $2.52 and a 12-month high of $9.37.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.